Carrick Therapeutics Limited

This early-stage study tested the safety and side effects of a new oral drug called CT7001 in people with advanced solid tumors that had stopped responding to standard treatments. It involved 124 participants and looked at CT7001 given alone and in combination with other cancer t…

This study tested whether adding an experimental drug called samuraciclib to the standard hormone therapy fulvestrant could better control advanced breast cancer that has stopped responding to prior treatments. It involved 60 adults with hormone receptor-positive, HER2-negative b…

This study tested whether combining two drugs, samuraciclib and elacestrant, is safe and effective for people with advanced hormone-positive, HER2-negative breast cancer that has progressed on standard therapy. It involved 49 adult participants internationally. The trial first ai…